ASCO 2017 - Lung Cancer - Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Patients

Video

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Mutation Positive Patients.

Targeted Therapy as Adjuvant Treatment: Should We Extrapolate from Advanced NSCLC to Earlier Stage?

Article

This past week, I saw a new patient who had just moved from another part of the country and needed long-term management of her high risk lung cancer.  A never-smoking Asian woman, she was found to have a stage IIIA lung cancer with "N2" mediastinal lymph nodes involving cancer in her mid-chest.

Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Article

Dr. Rosalyn Juergens, McMaster University, addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential use in the adjuvant setting.

[powerpress]

Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Article

Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

[powerpress]

Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Article

Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

[powerpress]